# US 2022/0033919 A1 · Method for detecting and quantifying latent retroviral rna species

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033919 A1
- Document ID: US20220033919A1
- Status: Published application
- Kind: A1
- Application number: 17/502,251
- Filed: 2021-10-15
- Published: 2022-02-03
- Earliest claimed: 2013-12-31
- Assignees: Bio-Rad Laboratories, Inc.
- Applicants: Bio-Rad Laboratories, Inc.
- Inventors: Michael L. Samuels; Darren R. Link; Sirshendu Roopom Banerjee
- Web page: https://patentgrep.com/patent/US20220033919A1

## CPC

- C12Q 1/702: {for retroviruses}
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention includes methods for determining the presence of a latent viral population by analyzing an RNA population from the virus with digital techniques, such as digital PCR or by sequencing cDNA produced from the RNA. The invention additional includes methods for determining the presence of latent viral populations by detecting and/or quantifying enzymes that are uniquely associated with the virus, e.g., reverse transcriptases.

## Claims

### Claim 1

A method for detection of latent retrovirus, comprising the steps of:
isolating a virion particle in an aqueous droplet surrounded by an immiscible fluid;
lysing the virion particle in the aqueous droplet to release an RNA molecule;
exposing the RNA molecule to at least one primer capable of hybridizing to at least a portion of the RNA molecule;
synthesizing a cDNA product from the RNA molecule; and
detecting the cDNA product.

### Claim 2 (depends on 1)

The method of claim 1, wherein detecting comprises amplifying the cDNA product to produce a plurality of substantially identical copies of the cDNA product.

### Claim 3 (depends on 2)

The method of claim 2, further comprising sequencing the substantially identical copies of the cDNA product to produce sequence reads.

### Claim 4 (depends on 2)

The method of claim 2, wherein the copies of cDNA product are detected with fluorescence detection.

### Claim 5 (depends on 1)

The method of claim 1, wherein said detecting step comprises quantifying said cDNA.

### Claim 6 (depends on 1)

The method of claim 1, further comprising introducing an amount of exogenous synthetic RNA, DNA, or mRNA.

### Claim 7 (depends on 6)

The method of claim 6, further comprising normalizing the detected cDNA against the exogenous synthetic RNA, DNA, or mRNA.

### Claim 8 (depends on 1)

The method of claim 1, further comprising collecting the virion particle from an isolated biological sample.

### Claim 9 (depends on 8)

The method of claim 8, wherein the isolated biological sample is a T-cell.

### Claim 10 (depends on 9)

The method of claim 9, wherein the T-cell is a CD4+ T cell.

### Claim 11 (depends on 1)

The method of claim 1, wherein the latent retrovirus a human immunodefficiency virus (HIV).

### Claim 12

A method for detecting a latent retrovirus species, the method comprising the steps of:
isolating virion RNA in an aqueous droplet surrounded by an immiscible fluid,
exposing the virion RNA in the droplet to at least one primer capable of hybridizing to at least a portion of the virion RNA;
synthesizing a cDNA product from the virion RNA; and
detecting the cDNA product.

### Claim 13 (depends on 12)

The method of claim 12, wherein detecting comprises amplifying the cDNA product to produce a plurality of substantially identical copies of the cDNA product.

### Claim 14 (depends on 13)

The method of claim 13, further comprising sequencing the substantially identical copies of the cDNA product to produce sequence reads.

### Claim 15 (depends on 13)

The method of claim 13, wherein the copies of cDNA product are detected with fluorescence detection.

### Claim 16 (depends on 12)

The method of claim 12, wherein said detecting step comprises quantifying said cDNA.

### Claim 17 (depends on 12)

The method of claim 12, further comprising introducing an amount of exogenous synthetic RNA, DNA, or mRNA.

### Claim 18 (depends on 17)

The method of claim 17, further comprising normalizing the detected cDNA against the exogenous synthetic RNA, DNA, or mRNA.

### Claim 19 (depends on 12)

The method of claim 12, further comprising collecting the virion particle from an isolated biological sample.

### Claim 20 (depends on 19)

The method of claim 19, wherein the isolated biological sample is a T-cell.
